MARKET

BOLD

BOLD

Audentes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.10
-0.32
-1.17%
Closed 16:11 11/13 EST
OPEN
27.31
PREV CLOSE
27.42
HIGH
27.52
LOW
26.99
VOLUME
355.80K
TURNOVER
--
52 WEEK HIGH
41.65
52 WEEK LOW
17.95
MARKET CAP
1.24B
P/E (TTM)
-6.8048
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BOLD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BOLD News

  • Audentes Therapeutics, Inc. (BOLD) CEO Matt Patterson on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3d ago
  • Audentes Therapeutics EPS beats by $0.06
  • seekingalpha.6d ago
  • Audentes Therapeutics Q3 EPS $(1) Beats $(1.07) Estimate
  • Benzinga.6d ago
  • Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
  • Business Wire.6d ago

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About BOLD

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
More

Webull offers Audentes Therapeutics Inc (BOLD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.